Sandbox gc3: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{| style="border: 2px solid #4479BA; align="left" ! style="width: 800px; background: #4479BA;"|{{fontcolor|#FFF|Most Common Grade ≥3 Non-Serious Adverse Events}} ! style="wi...")
 
mNo edit summary
Line 1: Line 1:
{| style="border: 2px solid #4479BA; align="left"
{| style="border: 2px solid #4479BA; align="left"
! style="width: 800px; background: #4479BA;"|{{fontcolor|#FFF|Most Common Grade ≥3 Non-Serious Adverse Events}}
! colspan=2 style="width: 800px; background: #4479BA; text-align: left;"|{{fontcolor|#FFF|Hepatic Laboratory Abnormalities—Study GS-US-540-5773}}
! style="width: 200px; background: #4479BA;"|{{fontcolor|#FFF|Remdesivir}}
! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Remdesivir for 5 Days}}
! style="width: 200px; background: #4479BA;"|{{fontcolor|#FFF|Placebo}}
! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Remdesivir for 10 Days}}
! style="width: 200px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Total}}
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Anemia or decreased hemoglobin
| rowspan=2 style="padding: 0 5px; background: #F5F5F5; text-align: left;" | ALT Increased
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 43 (8%)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 3
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 47 (9%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 8/194 (4%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 11/191 (6%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 19/385 (5%)
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Acute kidney injury, decreased eGFR or creatinine renal clearance, or increased blood creatinine
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Grade 4
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 40 (7%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 4/194 (2%)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 38 (7%)
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 5/191 (3%)
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: center;" | 9/385 (2%)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Pyrexia
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 27 (5%)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 17 (3%)
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Hyperglycemia or increased blood glucose
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 22 (4%)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 17 (3%)
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Increased transaminases, including ALT and/or AST
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 22 (4%)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 31 (6%)
|-
|-
|}
|}

Revision as of 21:05, 2 July 2020

Hepatic Laboratory Abnormalities—Study GS-US-540-5773 Remdesivir for 5 Days Remdesivir for 10 Days Total
ALT Increased Grade 3 8/194 (4%) 11/191 (6%) 19/385 (5%)
Grade 4 4/194 (2%) 5/191 (3%) 9/385 (2%)
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_gc3&oldid=1620867"